FDA recall record

Alvogen Adalat CC (nifedipine) Extended Release Tablets 30 mg, 100-count bottles recall — FDA D-0628-2017

Cross Contamination with another product:residual powder found in inlet air duct identified as sorafenib

Class IIIclassification
D-0628-2017official record ID
Apr 12, 2017report date

Recall record at a glance

Official recordD-0628-2017
CategoryDrug Recalls
ClassificationClass III
FDA record statusTerminated
Recalling firmAlvogen, Inc.
Report dateApr 12, 2017
Recall initiation dateMar 7, 2017
QuantityN/A
LocationPine Brook, NJ, United States

Official product description

Adalat CC (nifedipine) Extended Release Tablets 30 mg, 100-count bottles, Rx only, Manufactured for Bayer Healthcare Bayer Healthcare Pharmaceuticals Inc. Whippany, NJ 07901 Manufactured in Germany, NDC 50419-701-05

Why the product was recalled

Cross Contamination with another product:residual powder found in inlet air duct identified as sorafenib

Distribution information

Nationwide

How to read the classification

FDA Class III generally covers situations in which use of or exposure to the product is not likely to cause adverse health consequences. The classification displayed here is taken from the FDA enforcement record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: Letter.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.

Related recall records

Other records from the same recalling company are shown first when available.